newsfilter
← Latest News
GlobeNewswire·

Vigil Neuroscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Updates

– Announced positive data from Phase 1 clinical trial evaluating VG-3927 for potential treatment of Alzheimer's Disease (AD); plans to initiate Phase 2 clinical trial in Q3 2025 – – On track to report final analysis